SCHEMBL9605331

SCHEMBL9605331

Nc1ncnc2c1ncn2[C@@H]1OC(COCCP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 5/20 0.75
P2RY2 P41231 3/20 0.75
SRC P12931 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
TRPM2 O94759 2/20 0.75
TAS1R3 Q7RTX0 2/20 0.75
TAS1R1 Q7RTX1 2/20 0.75
P2RY11 Q96G91 2/20 0.75
DNPH1 O43598 1/20 0.75
PRKAB2 O43741 1/20 0.75
LDHA P00338 1/20 0.75
ADRB2 P07550 1/20 0.75
FBP1 P09467 1/20 0.75
ADORA1 P30542 1/20 0.75
PRKAG1 P54619 1/20 0.75
PRKAA2 P54646 1/20 0.75
PDE4D Q08499 1/20 0.75
KCNH2 Q12809 1/20 0.75
PRKAA1 Q13131 1/20 0.75
PDE3A Q14432 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13033869 1.00 P2RY1 (0.75) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL21839669 0.90 RNASEL (0.82) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL23915700 0.90 RNASEL (0.82) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL30395044 0.90 RNASEL (0.82) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL8328542 0.90 ADORA1 (0.74) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL4581742 0.87 P2RY1 (0.70) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL6828798 0.87 ADORA1 (0.70) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL2270709 0.87 ADORA1 (0.73) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL19420134 0.86 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL132458 0.86 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120135092-A1 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135092-A1 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS RECQL, WRN, ADAR P2RY1 299/4885P2RY2 553/4885SRC 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.